---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038052"
form_type: "8-K"
ticker: null
cik: "0001559356"
company_name: "Biostax Corp."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T14:04:55.104102+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biostax Corp (f/k/a Immune Therapeutics) name change to BTAX approved; pivots to substance abuse & HIV

## Summary
- Name change from Immune Therapeutics, Inc. to Biostax Corp effective Oct 5, 2023; FINRA approved Oct 20.
- New ticker symbol BTAX on OTC Pink Markets; old stock certificates remain valid.
- Strategic pivot to commercialize substance abuse solutions internationally and advance HIV treatment.
- Combining naltrexone technology with Immgenuity's IMTV014 vaccine platform for HIV/NeuroAIDS.
- CEO Noreen Griffin signals future commercial partnership updates and website launch in coming quarters.

## SEC filing metadata
- accession: 0001493152-23-038052
- form_type: 8-K
- cik: 0001559356
- company_name: Biostax Corp.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559356/000149315223038052/0001493152-23-038052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559356/000149315223038052/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038052
- JSON: https://secwatch.observer/filing/0001493152-23-038052.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038052.txt

## Key facts
- Governance Changes
  Biostax Corp.: Changed corporate name from Immune Therapeutics, Inc. to Biostax Corp (effective 2023-10-05).
  - Change: charter amendment
  - Effective: 2023-10-05
  source text: On October 5, 2023, Immune Therapeutics, Inc. d/b/a Biostax Corp (the “Company”) filed a Articles of Amendment to the Articles of Incorporation (“Amendment”) with the Secretary of State of the State of Florda to change its corporate name from Immune Therapeutics, Inc. to Biostax Corp., effective October 5, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1559356/000149315223038052/0001493152-23-038052-index.htm
- Governance Changes
  Biostax Corp.: Amended bylaws to reflect the corporate name change to Biostax Corp (effective 2023-10-05).
  - Change: bylaw amendment
  - Effective: 2023-10-05
  source text: In connection with the Company’s name change, the board of directors amended the Company’s bylaws to reflect the corporate name Biostax Corp., also effective on October 5, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1559356/000149315223038052/0001493152-23-038052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.